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Abstract
Objective: To assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled
patients with relapsing–remitting multiple sclerosis (RRMS).
Methods: Patients aged 18–50 years with RRMS (Expanded Disability Status Scale score #4.0) who had completed the 3-
year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsycho-
logical testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.
Results: Of 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of
whom (75.8%; sc IFN b-1a three times weekly: 44 mg, n = 108; 22 mg, n = 93) completed 5 years’ follow-up. The proportion of
patients with cognitive impairment in the study population overall remained stable between baseline (18.0%) and year 5
(22.6%). The proportion of patients with cognitive impairment also remained stable in both treatment groups between
baseline and year 5, and between year 3 and year 5. However, a significantly higher proportion of men than women had
cognitive impairment at year 5 (26.5% vs 14.4%, p = 0.046). Treatment with the 22 versus 44 mg dose was predictive of
cognitive impairment at year 5 (hazard ratio 0.68; 95% confidence interval 0.48–0.97).
Conclusions: This study suggests that sc IFN b-1a dose-dependently stabilizes or delays cognitive impairment over a 5-year
period in most patients with mild RRMS. Women seem to be more protected against developing cognitive impairment,
which may indicate greater response to therapy or the inherently better prognosis associated with female sex in MS.
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Introduction
Cognitive impairment is an important feature of multiple
sclerosis (MS), affecting up to 65% of patients [1]. Cognitive
symptoms may develop from the early stages of MS, sometimes as
the presenting symptoms, and in any form of the disease (clinically
isolated syndrome [CIS], relapsing–remitting MS [RRMS], or
primary or secondary progressive MS) [2]. Once present, cognitive
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symptoms are unlikely to resolve and the level of impairment is
believed to increase with worsening of physical disability [3],
disease duration [4,5], and the onset of progressive disease [4,5].
Deficits in memory, learning, attention, and information-process-
ing ability, most commonly observed in MS, may reflect damage
to specific brain regions that do not affect physical functioning.
Therefore, cognitive decline can indicate disease progression in
patients with stable physical function [5,6].
Cognitive symptoms alone can negatively affect many aspects
of patients’ daily lives, including employment and social
relationships, reducing overall quality of life [7,8]. In addition,
common MS comorbidities, such as fatigue and depression, can
impair cognitive function and further increase disability levels
[4,9,10].
Despite its high prevalence in MS, cognitive impairment is
rarely measured as part of standard clinical assessments because
many cognitive tests require specialist training and must be
administered by a certified neuropsychologist. In addition, tests are
often time consuming to perform [2]. For patients with cognitive
impairment, treatment is based on symptomatic therapies that aim
to optimize remaining cognitive function and thus reduce the
impact of cognitive decline [11,12]. Alternatively, pharmacological
treatment of comorbidities affecting cognitive performance can
provide benefits for patients, for example acetylcholinesterase
inhibitors, which are widely used to treat Alzheimer’s disease, may
also benefit patients with MS [13].
There is considerable evidence to indicate that disease-
modifying drugs (DMDs) can significantly improve outcomes for
patients with MS by reducing lesion development and improv-
ing clinical measures of disease, such as relapse rate [14]. The
observation that some magnetic resonance imaging (MRI)
disease measures, such as lesion load and brain volume,
correlate with cognitive impairment suggests that DMD
treatment may also prevent or delay cognitive decline by
attenuating inflammatory processes and preventing the devel-
opment of new brain lesions or progressive brain atrophy
[12,13]. However, as the pivotal trials of DMDs did not, in
general, include cognitive assessments, the cognitive benefits of
DMDs in patients with MS are unconfirmed.
The COGIMUS (COGnitive Impairment in MUltiple Sclero-
sis) study evaluated cognitive decline in mildly disabled Italian
patients with RRMS receiving treatment with interferon (IFN) b-
1a, 22 or 44 mg (RebifH; Merck Serono S.A., Switzerland),
administered subcutaneously (sc) three times weekly (tiw). In this
study, cognitive impairment was assessed using the Rao’s Brief
Repeatable Battery (BRB) and the Stroop Color–Word Task
(Stroop Test), which have been validated for use in patients with
MS and for which Italian normative values are available [15].
After 3 years’ follow-up, it was found that sc IFN b-1a may have
dose-dependent cognitive benefits in this patient group. At year 3,
the proportion of patients with cognitive impairment was
significantly higher in the 22 mg group than in the 44 mg group
(p = 0.03) and the risk of cognitive impairment was reduced by
32% with the 44 mg dose [16]. These findings may further support
early initiation of high-dose IFN b-1a treatment in patients with
RRMS. Here we report clinical and cognitive outcomes from the
2-year extension of the study, giving a total of 5 years’ follow-up.
Methods
COGIMUS was a prospective, 3-year, multicenter, observa-
tional, Italian cohort trial. Patients were enrolled between
September 2003 and March 2005. Methodological details have
been reported elsewhere [16]. Following completion of the study,
patients were eligible to enter a 2-year extension study, with a total
follow-up of 5 years.
Patients
Eligibility criteria have been previously described [17].
Briefly, patients were aged 18–50 years with a diagnosis of
RRMS (McDonald criteria), had an Expanded Disability Status
Scale (EDSS) score of #4.0 and were naı¨ve to DMD treatment.
All patients at participating centers who had completed the core
3-year study were invited to participate in the 2-year extension
study. All patients gave written informed consent prior to
undergoing any assessments not performed as part of their
routine care. The study protocol was first approved in
September 2003 by the ethics committee of Policlinico,
University of Catania, and then in the following 9 months by
the local ethics committees of: Garibaldi Hospital (Catania), San
Camillo Hospital (Rome), University Federico II of Naples,
Cardarelli Hospital (Naples), Careggi Hospital (Florence),
Orbassano Hospital (Piedmont Region), Palermo – ASP 6
(Sicily Region), University Tor Vergata (Rome), University of
Palermo, Prato Hospital (Tuscany Region), University of
Padova, University of Udine, Macerata Hospital (Marche
Region), Giglio–San Raffaele Hospital, ASP 7 (Sicily Region),
University of Chieti, University of Novara, Fidenza Hospital
(Emilia Romagna Region), Ascoli Piceno Hospital (Marche
Region), University of Ancona, University of Ferrara, University
of Bari, Sant’Antonio Abate Hospital (Gallarate, Lombardy
Region), Arezzo Hospital (Tuscany Region), University of
Trieste, State University of Milan, University of Torino, La
Spezia Hospital (Liguria Region), University of L’Aquila, and
Avellino Hospital (Campania Region). The study was conducted
in accordance with the principles expressed in the Declaration
of Helsinki.
Treatment
In the core study, patients were assigned to IFN-b treatment,
with the formulation and dose at the discretion of their treating
physician [16,17]. Of those who received sc IFN b-1a (N = 459),
223 (48.6%) received the 22 mg dose and 236 (51.4%) received the
44 mg dose. All patients who completed the 5-year follow-up
continued on the same treatment as at year 3 for the duration of
the extension study. Relapses were treated with corticosteroids,
and flu-like symptoms with non-steroidal anti-inflammatory drugs
or paracetamol. DMDs other than the study drug were not
permitted.
Study objectives and endpoints
The primary objective of the extension study was to determine
the effects of two doses of sc IFN b-1a on cognition over 5 years;
the primary endpoint was the proportion of patients with cognitive
impairment at year 5. The main secondary objective was to
identify factors that predicted the presence of cognitive impair-
ment after 5 years on study. In addition, discontinuations and
reasons for treatment discontinuation, and adverse events (AEs)
during years 3–5, were recorded. Patients who discontinued
treatment were followed regularly in the clinical trial setting and
were included in the analyses if they had cognitive assessments at
all time points, regardless of whether they had discontinued
treatment.
Evaluation of disease status
Clinical and MRI assessments during the core study have been
reported previously [17]. Patients attended two further visits at
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years 4 and 5 that comprised neurological assessment, including
EDSS score, recording of relapses, and MRI (25 of 34 centers to
year 3, and 19 centers from years 3 to 5).
Neuropsychological evaluation
All patients underwent neuropsychological evaluation at base-
line and every 12 months during the core study. Two further
neuropsychological assessments were performed at years 4 and 5,
as described previously [17], namely the BRB (alternate versions
administered in the order A, B, A, B) and the Stroop Test.
Cognitive impairment was defined as 1 standard deviation (SD)
below the mean Italian normative values for each cognitive test
[15]. Cognitive testing of patients who had an ongoing relapse at
the time of the scheduled assessment was delayed until 30 days
after the last steroid injection.
Statistical analyses
For outcome measures at 5 years, only patients with 5 years of
follow-up were included in the analyses. No imputation of missing
data was considered. Analyses at 5 years were exploratory without
adjustment for multiplicity. Cognitive data from baseline and years
1, 3, and 5 only (BRB version A) were analyzed to avoid
differences due to administration of alternate versions of the BRB.
The following tests were conducted: Pearson chi-square and
McNemar tests to compare categorized proportions, Cox propor-
tional hazards regression to compare longitudinal data on
cognitive impairment, Cochran test for k-related samples to assess
variation over time in the percentage of patients with cognitive
impairment, and Friedman test for k-related samples to assess
variation over time in the number of impaired tests in the study
population and each treatment group. In addition, Kaplan–Meier
survival curves were constructed to evaluate longitudinal differ-
ences between treatments. Risk factors for the presence of
cognitive impairment over 5 years were identified using a
multivariate regression model, which was developed by sequen-
tially adding variables with a significant hazard ratio in univariate
analyses. Statistical significance was set at 0.05.
Results
Patients and baseline characteristics
Of the 40 original participating centers, 23 (accounting for
80.1% [265/331] of patients from the 3-year follow-up cohort)
participated in the extension study. Of the 265 eligible patients,
201 (75.8%; sc IFN b-1a tiw: 44 mg, n = 108; 22 mg, n = 93)
completed the 5-year follow-up and were included in these
analyses. The mean duration of follow-up was 5.6 years (range
4.5–6.1 years). Mean (SD) age was 39 (8.2) years and mean (SD)
disease duration was 8 (4.4) years (mean [SD] disease duration at
baseline: 3.9 [4.4 years]). No differences were found between
patients who did or did not participate in the 5-year follow-up in
terms of baseline clinical and demographic characteristics,
neuropsychological performance, or proportions receiving the 44
or 22 mg dose, with the exception of mean (SD) Environmental
Status Scale score, which was greater in patients who had the 5-
year follow-up (1.63 [2.5]) than those who did not (1.29 [2.4]). The
male:female ratio was 0.6. Overall, there was no difference in the
proportion of patients with or without cognitive impairment at
year 3 (the end of the core study) who went on to participate in the
2-year extension study and complete the 5-year follow-up (Pearson
chi-squared test = 0.574; Table 1).
Between years 3 and 5, 64 patients discontinued treatment.
Discontinuation rates were similar in both IFN b-1a groups: 35
patients receiving 44 mg and 29 patients receiving 22 mg. Reasons
for discontinuation were: AEs, 5 (7.8%) patients; lost to follow-up,
28 (43.8%); lack of efficacy, 11 (17.2%); pregnancy/planning to
conceive, 10 (15.6%); other, 10 (15.6%). ‘Other’ reasons were
predominantly subjective, such as ‘patient decided not to
continue’. There were no discontinuations due to injection-site
reactions.
Cognitive impairment at 5 years
A Cox proportional hazards survival analysis was performed to
assess the development of cognitive impairment (proportion of
patients with $3 impaired cognitive tests) during the 5-year study.
Figure 1 shows Kaplan-Meier survival curves for this analysis, by
treatment (discussed further below). The overall proportion of
patients with cognitive impairment did not increase significantly
over the 5-year period. Among patients with data available at all
time points, the proportion with cognitive impairment was 18.0%
at baseline and 22.6% at year 5 (Cochran test = 0.392; Table 2).
Similarly, only small and non-significant increases were seen in the
proportion of patients with cognitive impairment in each
treatment group. In the 44 mg group, 15.6% of patients at
baseline and 16.7% at year 5 had cognitive impairment; in the
22 mg group, the corresponding proportions were 20.5% and
21.7% (Figure 2a). The proportion of patients with cognitive
impairment also remained stable between 3 and 5 years’ follow-up
in both the 44 mg group (18.1% vs 16.0%, respectively) and 22 mg
group (21.8% vs 21.8%, respectively; Figure 2b). The mean (SD)
number of cognitive tests of impairment did not differ significantly
over time, neither in the entire study cohort nor in either
treatment group, except for baseline versus year 1 in the 22 mg
group (1.4 [1.7] vs 1.8 [2.0]; p = 0.020).
Predictors of cognitive impairment at year 5
Kaplan-Meier survival curves confirmed the benefits of
receiving the higher versus the lower dose of sc IFN b-1a
treatment on cognitive impairment during the 5-year study
(Figure 1). The hazard ratio (95% confidence interval) for the
44 mg versus 22 mg dose was 0.68 (0.48–0.97) over 5 years.
At year 5, the proportion of men with cognitive impairment was
significantly higher than the proportion of women (26.5% [18/68]
vs 14.4% [16/111], p = 0.0459; Figure 3).
Clinical outcomes
Over the 5-year period, the mean relapse rate per patient per
year was 0.21. The mean relapse rate remained stable between
years 3 and 5. Median EDSS scores also remained stable between
years 3 and 5 (median score at year 5: 2.0; interquartile range 2).
The proportion of patients who were free from disability
progression (as assessed by EDSS score) was 84% at year 3 and
71% at year 5. At the 5-year follow-up, 82% of patients who had
been progression-free at year 3 had an unchanged level of physical
disability. The proportion of patients who were free from disease
progression at year 5 was similar in those with and without
cognitive impairment at year 5 (33% vs 27%, respectively). There
were no differences in clinical outcomes between treatment
groups.
Safety
AEs were consistent with the known safety profile of IFN b-1a
[18]. The most common AEs reported over the 5-year follow-up
were injection-site reactions (30% of patients), flu-like symptoms
(15% of patients), and depression (2% of patients). Overall, 50% of
AEs were classified as mild in severity.
Interferon Iˆ2-1a and Cognitive Function in MS
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Discussion
In this extension study, we found that, in the study population as
a whole, the proportion of patients with impaired cognitive
function remained stable over the 5 years of follow-up. However,
after 5 years of treatment with IFN b-1a, a higher percentage of
men than women had cognitive impairment. These results suggest
that sc IFN b-1a may have a protective effect on cognitive
performance and that this effect may be greater in women than in
men.
The current finding that the level of cognitive impairment
remained stable during the 5 years confirms and extends our
previous observations [16], suggesting that sc IFN b-1a may
stabilize cognitive function in mildly disabled patients with MS.
Natural history studies of cognitive impairment in patients with
MS indicate that cognitive performance would be expected to
decline by approximately 5% per year in this patient group [6].
Indeed, the proportion of patients with cognitive impairment has
been reported to increase substantially from 29% to 54% during
the first 5 years after a CIS [19], and from 52.3% to 71.4% in the
first 7 years, after diagnosis of MS [8]. Significant cognitive
deterioration over 5 years in patients with CIS or MS with a
disease duration of#6 years has also been reported, particularly in
the domains of working memory, speed of information processing,
and spatial memory [20]. In contrast, we found no significant
increase in the proportion of patients with cognitive impairment
over the same timeframe in the 5-year follow-up cohort (mean
[SD] duration of disease at baseline: 3.9 [4.4 years]). Considering
that cognitive function would be expected to deteriorate over 5
years in the absence of treatment, including in patients with intact
cognitive function at baseline [21], the present results confirm our
previous findings suggesting that sc IFN b-1a can prevent or delay
the onset of cognitive symptoms in patients with MS [16]. Our
observation of a dose effect, with the 44 mg dose of sc IFN b-1a
being a significant predictor of absence of cognitive impairment at
year 5, provides further evidence of a beneficial treatment effect.
How IFN b-1a treatment may bring about cognitive benefits is
an interesting topic for debate. A likely explanation is that
cognitive effects are a result of the known anti-inflammatory
actions of IFN b, which reduce lesion development in the central
nervous system (CNS). Correlations between cognitive function
and MRI measures of disease have been reported [2], thus
supporting this theory. There is increasing evidence to indicate
Table 1. Proportion of patients with and without cognitive impairment at year 3 (end of the core study) who did/did not complete
follow-up at year 5.
Cognitive status at year 3 (n=265) Completed 5-year follow-up,%
No (n = 64) Yes (n = 201) Total Pearson chi-squared test
Not impaired (n = 216) 79.49 81.92 80.78 0.574
Impaired (n = 49) 20.51 18.08 19.22
Total 100.0 100.0 100.0
doi:10.1371/journal.pone.0074111.t001
Figure 1. Kaplan–Meier survival curve for patients without cognitive impairment at baseline. Development of cognitive impairment (i.e.
impaired performance on $3 cognitive tests) over 5 years in patients receiving IFN b-1a treatment (22 or 44 mg sc tiw). Cl, confidence interval; HR,
hazard ratio; IFN, interferon; sc, subcutaneously; tiw, three times weekly.
doi:10.1371/journal.pone.0074111.g001
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that MS-related changes in cortical matter (lesions and atrophy)
play a major role in the development of cognitive symptoms [22].
Recently, sc IFN b-1a has been shown to significantly decrease the
development of new cortical lesions and cortical atrophy, which
could further explain how sc IFN b-1a protects against cognitive
decline in patients with MS [23].
In addition to its immunomodulatory properties, IFN b may
also indirectly protect against neuronal damage or promote repair
by increasing the production of neurotrophic factors, including
nerve growth factor and brain-derived neurotrophic factor
[24,25]. However, the relationship between neurotrophic factor
production and cognitive outcomes in patients with MS has not
been studied.
Our observation that a greater proportion of men than women
had cognitive impairment at year 5 is intriguing, particularly as
this difference was not observed at the end of the 3-year core
study, and suggests a better response to sc IFN b-1a in women, at
least for this outcome. As in other autoimmune diseases, sex
differences have been reported in MS susceptibility [26–28].
Differences in disease course and severity have also been
highlighted, with male sex being associated with a more
progressive form of the disease and worse outcomes [28,29].
Indeed, large epidemiological studies have shown that men reach
the same level of disability (EDSS score) as women in a shorter
time from diagnosis, are more likely to present with a primary
progressive course, and are more susceptible to destructive lesions
than women; in contrast, inflammatory lesions seem to be more
prevalent in women [30,31].
The underlying causes of these sex differences are unknown;
however, genetic predisposition between sexes [32,33], the
modulation of immune responses by sex hormones, inflammatory
processes, tissue injury and repair mechanisms, and possible
neuroprotective effects seem to play a part [34,35]. Consistent with
a role for sex hormones is the observation that relapse rates
decrease during pregnancy and increase post partum [36,37]. Our
current findings are in agreement with previous studies showing a
differential response to IFN b in women and men with MS
regarding disability progression [38], although another study in
patients with RRMS did not find sex differences regarding
response to intramuscular IFN b-1a [39]. It is also possible that the
apparent lower response to IFN b-1a in men seen here is, in fact,
simply due to the inherently worse prognosis in men; that is, in the
absence of treatment, the degree of cognitive decline in men may
have been even greater than was observed.
COGIMUS confirmed that cognitive impairment affects a
significant proportion of patients from the early stages of MS: over
half of all patients in this cohort had impaired performance on at
least one cognitive test despite being at an early stage of the disease
and having a mild level of disability at study entry [16]. As existing
cognitive impairment is a risk factor for further cognitive decline
[40], it is clearly important that patients with cognitive symptoms
are identified and their treatment tailored as necessary. However,
the observation that cognitive impairment can develop during the
first 5 years of the disease in patients who previously had no
evidence of cognitive symptoms highlights that all patients are
potentially at risk of cognitive impairment [19]. The importance of
initiating early DMD treatment to prevent or slow the accumu-
lation of damage to the CNS, including brain atrophy [41], and
thus physical disability, is now recognized. As cognitive decline
occurs in the absence of ongoing relapse or disability progression
even in the early stages of disease [21], our findings suggest that
early IFN-b treatment may not only protect those with cognitive
symptoms from further cognitive decline, but may also prevent the
development of cognitive impairment. Whether these observations
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reflect the prevention of damage to cortical tissue would be an
interesting topic for further investigation.
Limitations of this study should be considered when interpreting
these findings. The lack of an untreated control group and study
discontinuation rate of over 20% between year 3 and completion
of the 2-year extension limit the conclusions that can be drawn
regarding efficacy. Several centers from the original trial did not
participate in the extension phase, accounting for a considerable
proportion of the reduction in patient numbers between baseline
and year 5. There may also have been a selection bias for patients
who are doing well on treatment; patients with declining cognitive
function may have been more likely to drop out. However, as
there was no significant difference between the proportion of
patients with or without cognitive impairment at year 3 who
participated in the extension study, cognitive impairment at the
end of the core study did not appear to be a predictor of lack of
participation at year 5. One limitation in this respect is the lack of
availability of patient data at year 4. Furthermore, because
cognitive performance was evaluated using a different version of
the BRB (version B) in year 2 from that used in years 1, 3, and 5
(version A), and the two versions differ slightly regarding the
weight given to some cognitive functions, year 2 data were
excluded from the analysis to ensure that the longitudinal data
were comparable. Finally, the differential effects in men and
women could have been influenced by the different numbers of
men and women, or by other possible differences between the
sexes, such as adherence to treatment, which were not assessed.
Despite the limitations, the results reported here add to the
evidence suggesting that sc IFN b-1a may have dose-dependent
cognitive benefits in patients with RRMS. Here we also
demonstrate that these benefits persist over at least 5 years of
treatment and may be more pronounced in women than in men,
although it is possible that the sex difference reflects inherently
poorer prognosis in men. Additionally, sc IFN b-1a was shown to
achieve good disease control and was well tolerated. Our results
further support the clinical benefit of initiating sc IFN b-1a
treatment, even in patients with mild physical disability.
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